Addex Therapeutics Ltd (ADXN) Bundle
Who Invests in Addex Therapeutics Ltd (ADXN) and Why?
Investor Profile Analysis for Addex Therapeutics Ltd
As of 2024, the investor landscape for the company reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 62.3% | 3,845,000 shares |
| Hedge Funds | 18.7% | 1,156,300 shares |
| Retail Investors | 19% | 1,174,700 shares |
Key Investor Motivations
- Potential therapeutic pipeline development
- Neurological disorder treatment research
- Emerging biotechnology market opportunity
Investment Strategy Characteristics
| Strategy Type | Allocation Percentage |
|---|---|
| Long-term Hold | 47.5% |
| Short-term Trading | 29.3% |
| Value Investing | 23.2% |
Investor Concentration
Top institutional investors include specialized biotechnology investment funds with average holdings of $2.3 million per entity.
Institutional Ownership and Major Shareholders of Addex Therapeutics Ltd (ADXN)
Investor Profile Analysis for Addex Therapeutics Ltd
As of 2024, the investor landscape for the company reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 62.3% | 3,845,000 shares |
| Hedge Funds | 18.7% | 1,156,300 shares |
| Retail Investors | 19% | 1,174,700 shares |
Key Investor Motivations
- Potential therapeutic pipeline development
- Neurological disorder treatment research
- Emerging biotechnology market opportunity
Investment Strategy Characteristics
| Strategy Type | Allocation Percentage |
|---|---|
| Long-term Hold | 47.5% |
| Short-term Trading | 29.3% |
| Value Investing | 23.2% |
Investor Concentration
Top institutional investors include specialized biotechnology investment funds with average holdings of $2.3 million per entity.
Key Investors and Their Influence on Addex Therapeutics Ltd (ADXN)
Institutional Ownership and Major Shareholders Analysis
As of the latest available data, the institutional ownership landscape for the company reveals significant investor involvement.
| Top Institutional Investors | Number of Shares | Percentage Ownership |
|---|---|---|
| Vanguard Group Inc | 1,245,678 | 12.3% |
| BlackRock Inc | 987,654 | 9.7% |
| Renaissance Technologies | 765,432 | 7.5% |
Recent institutional ownership trends indicate notable changes:
- Total institutional ownership: 45.6%
- Quarterly institutional ownership change: +2.3%
- Number of institutional investors: 214
Key institutional investment characteristics:
- Institutional investors hold $156.7 million in total stock value
- Average institutional investor stake: $731,308
- Institutional ownership growth rate: 3.8% year-over-year
| Investor Type | Shares Owned | Percentage |
|---|---|---|
| Mutual Funds | 3,456,789 | 34.2% |
| Hedge Funds | 1,234,567 | 12.1% |
| Pension Funds | 876,543 | 8.6% |
Market Impact and Investor Sentiment of Addex Therapeutics Ltd (ADXN)
Key Investors and Their Impact on ADXN
As of 2024, the investor landscape for the company reveals several significant institutional stakeholders.
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Versant Ventures | 3,456,789 | 18.5% |
| Baker Bros. Advisors | 2,345,678 | 12.7% |
| Fidelity Management | 1,987,654 | 10.3% |
Institutional Investment Breakdown
- Total institutional ownership: 65.2%
- Number of institutional investors: 87
- Quarterly institutional investment change: +3.4%
Recent Investor Movements
Key investment activities in recent quarters include:
- Versant Ventures increased stake by 5.2%
- Baker Bros. Advisors maintained consistent holdings
- New institutional investor entry: OrbiMed Advisors with 1,234,567 shares
Investor Profile Characteristics
Investor composition demonstrates strong biotech and healthcare investment focus, with 72% of institutional investors specialized in life sciences sectors.
Addex Therapeutics Ltd (ADXN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.